The treatment of metabolic dysfunction-associated steatohepatitis (MASH) has proven challenging, with many compounds failing during development for various reasons. However, with the recent ...
2hon MSN
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...
The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...
US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...
Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...
WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.
Not only did I not know that longtime local brewery Novo Brazil had opened a new spot in the Mission Valley Mall, but I also ...
The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.
As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback